Generic Name and Formulations:
Mycophenolate mofetil (as hydrochloride) 500mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free; contains polysorbate 80.
Organ rejection prophylaxis in allogeneic renal, cardiac, or hepatic transplant patients, in combination with cyclosporine and corticosteroids.
Administer within 24hrs after transplantation. Give by slow IV infusion over ≥2hrs. Renal or hepatic: 1g twice daily (2g/day). Cardiac: 1.5g twice daily (3g/day). May treat up to 14 days. Switch to oral forms when tolerated. Severe renal impairment: see full labeling.
Hypersensitivity to other forms of mycophenolate. IV: polysorbate 80 allergy.
Embryo-fetal toxicity; rule out pregnancy with serum or urine pregnancy test immediately before starting therapy, then another test 8–10 days later. Repeat pregnancy tests during routine follow-up visits. Increased risk of infections, lymphomas and other malignancies (eg, skin). Avoid sun, UV light. Monitor CBCs weekly for 1 month, twice monthly for 2 months, then monthly during first year. If ANC <1300/µL, discontinue or reduce dose. Active GI disease or renal impairment (monitor). Hypoxanthine-guanine phosphoribosyl transferase deficiency; avoid. Oral susp: phenylketonuria. Elderly. Pregnancy (Cat.D); avoid. Females of reproductive potential must be counseled on using 2 forms of contraception (or 1 form if using IUDs, tubal sterilization, or if partner has had vasectomy) during therapy, and for 6 weeks after discontinuation unless patient chooses abstinence. Nursing mothers: not recommended.
Concomitant azathioprine, live vaccines, rifampin, cholestyramine, drugs that interfere with enterohepatic recirculation, or the combination of norfloxacin and metronidazole: not recommended. Antagonized by antacids (separate dosing), PPIs (use with caution), drugs that alter GI flora, telmisartan. May antagonize oral contraceptives; use additional birth control methods. May potentiate or be potentiated by acyclovir, ganciclovir, probenecid. Antagonized by sevelamer and other calcium-free phosphate binders; may give 2hrs after mycophenolate mofetil. Caution when concomitant cyclosporine A and then switching to other immunosuppressants (eg, tacrolimus, belatacept).
Blood dyscrasias, constipation, diarrhea, vomiting, peripheral edema, hypertension, new or reactivated infections (eg, UTI, cytomegalovirus, sepsis, herpes), progressive multifocal leukoencephalopathy, pure red cell aplasia (w. concomitant immunosuppressants), malignancies (eg, lymphomas, skin), insomnia; rare: GI bleeding, ulceration, perforation. IV: phlebitis, thrombosis.
Encourage pregnant patients to enroll in the Mycophenolate Pregnancy Registry by calling (800) 617-8191.
Renal (major), fecal.
Caps, tabs (YES); inj, susp (NO)
Caps, Tabs—100, 500; Susp—225mL (w. bottle adapter and 2 oral dispensers); Vials (20mL)—4
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
Fever in adults can have potentially serious causes, ranging from sepsis to malignancy. Dr Pipin Singh...
In this article Dr Pipin Singh advises on how to identify red flags in patients presenting with bone...
Dr Matthew West covers the red flags to look out for in pregnancy, including back pain, bleeding, headaches...
This article, updated in 2016 by Dr Anthony De Soyza, advises on causes, investigations and managing...
Dr Keith Barnard discusses the aetiology and symptoms of Brugada syndrome. Key learning points for GPs...
Dr Kirsty Le Doare and Dr Nuria Martinez-Alier describe the signs and symptoms of measles and outline...